Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
NCT07923084, Recruiting, Insel Gruppe AG, University Hospital Bern
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage | ClinicalTrials.gov |
| NCT number | NCT07923084 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 264 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Insel Gruppe AG, University Hospital Bern | ClinicalTrials.gov |
| Conditions | Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal, Perimesencephalic Subarachnoid Hemorrhage, Basilar Artery Perforator Aneurysm | ClinicalTrials.gov |
| Interventions | Completion of a patient-reported outcome measure (PROM) in the form of a EQ-5D questionnaire | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Rate of BAPAs in pmSAH where at least one high-resolution 3D-rotational angiography (3D-RA) of the dominant vertebral artery was performed within 7 days after the index presentation | Within 7 days after pmSAH diagnosis | ClinicalTrials.gov | |
| Secondary | Rate of patients with excellent functional outcome (Modified Rankin Scale 0-1) at 3 months | 3 months after enrollment | ClinicalTrials.gov | |
| Secondary | Rate of patients with favorable functional outcome (Modified Rankin Scale 0-2) at 3 months | 3 months after enrollment | ClinicalTrials.gov | |
| Secondary | Patient-Reported Outcome (EQ-5D-5L questionnaire) at 3 months | 3 months after enrollment | ClinicalTrials.gov | |
| Secondary | Modified Rankin Scale (mRS, range 0-6 with higher scores indicating worse functional status) at hospital discharge | 21 days after enrollment or hospital discharge (if discharged earlier) | ClinicalTrials.gov | |
| Secondary | National Institutes of Health Stroke Scale (NIHSS, range 0-42 with higher scores indicating greater neurological impairement) at hospital discharge | 21 days after enrollment or hospital discharge (if discharged earlier) | ClinicalTrials.gov | |
| Secondary | Rate of rebleeding | From enrollment to 3-month follow-up | ClinicalTrials.gov | |
| Secondary | Rate of hydrocephalus requiring EVD or lumbar drain | From enrollment to 3-month follow-up | ClinicalTrials.gov | |
| Secondary | Rate of symptomatic vasospasm | From enrollment to 3-month follow-up | ClinicalTrials.gov | |
| Secondary | Rate of BAPAs in pmSAH overall (regardless of 3D-RA acquisition) | From enrollment to 3-month follow-up | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 14
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 1681340 | BACKGROUND | PubMed |
| 1950905 | BACKGROUND | PubMed |
| 16931020 | BACKGROUND | PubMed |
| 25801775 | BACKGROUND | PubMed |
| 27173362 | BACKGROUND | PubMed |
| 29695465 | BACKGROUND | PubMed |
| 31597686 | BACKGROUND | PubMed |
| 32194275 | BACKGROUND | PubMed |
| 35059755 | BACKGROUND | PubMed |
| 36119687 | BACKGROUND | PubMed |
| 36283807 | BACKGROUND | PubMed |
| 36778213 | BACKGROUND | PubMed |
| 38129710 | BACKGROUND | PubMed |
| 42448461 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)